Page 165 - Haematologica-5

References
1. National Cancer Institute. Surveillance epi- demiology and end results program. SEER stat fact sheets: Myeloma. 2013; http://seer.cancer.gov/statfacts/html/mulmy .html [Last accessed 14 April 2017].
2. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516-2520.
3. PalumboA,AndersonK.Multiplemyeloma. N Engl J Med. 2011; 364(11):1046-1060.
4. Touzeau C, Moreau P. How I treat
extramedullary myeloma. Blood. 2016;
127(8):971-976.
5. Bladé J, Fernández de Larrea C, Rosiñol L,
Cibeira MT, Jiménez R, Powles R. Soft-tis- sue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29(28):3805-3812.
6. Weinstock M, Aljawai Y, Morgan EA, et al. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplan- tation. Br J Haematol. 2015;169(6):851-858.
7. Cavo M, Terpos E, Nanni C, et al. Role of 18F-FDG PET/CT in the diagnosis and man- agement of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18(4):e206-e217.
8. Bartel TB, Haessler J, Brown TL, et al. F18- fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multi- ple myeloma. Blood. 2009; 114(10):2068- 2076.
9. Usmani SZ, Heuck C, Mitchell A, et al. Extramedullary disease portends poor prog- nosis in multiple myeloma and is overrepre- sented in high-risk disease even in the era of
novel agents. Haematologica. 2012;97(11):4761-4767.
10. Short KD1, Rajkumar SV, Larson D, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy and the activity of pomalido- mide in extramedullary myeloma. Leukemia. 2011;25(6):906-908.
11. Rosiñol L, Fernández de Larrea C, Bladé J. Extramedullary myeloma spread triggered by surgical procedures: an emerging entity? Acta Haematol. 2014;132(1):36-38.
12. Pérez-SimónJA,SuredaA,Fernández-Aviles F, et al. Reduced-intensity conditioning allo- geneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia. 2006;20(3):542-545.
13. Varettoni M1, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myelo- ma: a longitudinal study on 1003 consecu- tive patients. Ann Oncol. 2010;21(2):325- 330.
14. Rosiñol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pre- transplantation therapy in multiple myelo-
risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955-2962.
17. Cavo M, Rajkumar SV, Palumbo A, et al. International Myeloma Working Group con- sensus approach to the treatment of multi- ple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011;117(23):6063-6073.
18. Bianchi G, Richardson PG, and Anderson KC. Best Treatment Strategies in High-Risk Multiple Myeloma: Navigating a Gray Area. J Clin Oncol. 2014;32(20):2125-2132.
19. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progres- sion in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998; 102(5):1115-1123.
20. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412- 3420.
21. Durie BG, Salmon SE. A clinical staging sys- tem for multiple myeloma. Correlation of measured myeloma cell mass with present- ing clinical features, response to treatment, and survival. Cancer. 1975;36(3):842-854.
22. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The Use of the Nitrogen Mustards in the Palliative Treatment of Carcinoma – with Particular Reference to Bronchogenic Carcinoma. Cancer. 1948;1(4):634-56.
23. Kaplan E, Meier P. Nonparametric estima- tion from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
24. Schemper M, Smith TL. A note on quantify- ing follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343-346.
25. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a compet- ing risk. J Am Stat Assoc. 1999;94(446):496- 509.
26. Gray RJ. A class of k-sample tests for com- paring the cumulative incidence of a com- peting risk. Ann Stat. 1988;16(3):1141-1154.
27. Iacobelli S, EBMT Statistical Committee. Suggestions on the use of statistical method- ologies in studies of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2013;48(Suppl 1):S1-37.
28. Klein JP, Moeschberger ML (eds): Survival Analysis: Techniques for Censored and Truncated Data, 2nd edn. Springer-Verlag: New York, USA, 2003.
29. Cox DR: Regression models and life tables. J R Stat Soc B. 1972;34(2):187-220.
30. Lee SE, Kim JH, Jeon YW, et al. Impact of extramedullary plasmacytomas on out- comes according to treatment approach in newly diagnosed symptomatic multiple myeloma. Ann Hematol. 2015; 94(3):445- 452.
31. Pour L, Sevcikova S, Greslikova H, et al. Soft-tissue extramedullary multiple myelo- ma prognosis is significantly worse in com- parison to bone-related extramedullary relapse. Haematologica. 2014;99(2):360- 364.
32. Ghobrial IM. Myeloma as a model for the process of metastasis: implications for ther- apy. Blood. 2012;120(1):20-30.
33. Hu K, Yahalom J. Radiotherapy in the man- agement of plasma cell tumors. Oncology (Williston Park). 2000;14(1):101-108.
34. Terpos E, Morgan G, Dimopoulos MA, et al. International Myeloma Working Group
Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease. J Clin Oncol. 2013;31(18):2347-2357.
35. Paubelle E, Coppo P, Garderet L, et al. Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect. Leukemia. 2005;19(9):1702-1704.
36. Sonneveld P, Goldschmidt H, Rosiñol L, et al. Bortezomib-based versus nonborte- zomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III ran- domized, controlled trials. J Clin Oncol. 2013;31(26):3279-3287.
37. Mateos MV, Oriol A, Matínez-López J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and pred- nisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreat- ed multiple myeloma: a randomised trial. Lancet Oncol. 2010;11(10):934-941.
38. Muchtar E, Gatt ME, Rouvio O, et al. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory mul- tiple myeloma patients: a multicentre retro- spective observational study. Br J Haematol. 2016;172(1):89-96.
39. Calvo-Villas JM, Alegre A, Calle C, et al. Lenalidomide is effective for extramedullary disease in relapsed or refrac- tory multiple myeloma. Eur J Haematol. 2011;87(3):281-284.
40. Rosiñol L, Cibeira MT, Bladé J, et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica. 2004;89(7):832-836.
41. Nieuwenhuizen L, Biesma DH. Central nervous system myelomatosis: review of the literature. Eur J Haematol. 2008;80(1):1- 9.
42. Chen CI, Masih-Khan E, Jiang H, et al. Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents. Br J Haematol. 2013;162(4):483-488.
43. Cavo M, Salwender H, Rosiñol L, et al. Double vs single autologous stem cell trans- plantation after bortezomib-based induc- tion regimens for multiple myeloma: an integrated analysis of patient-level data from phase European III studies. Blood. 2013;122:767.
44. Moreau P, Attal M, Caillot D, et al. Prospective evaluation of magnetic reso- nance imaging and [18F] Fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. J Clin Oncol. 2017; 35(25):2911-2918.
45. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group con- sensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328- 346.
46. Pawlyn C, Fowkes L, Otero S, et al. Whole- body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma? Leukemia. 2016;30(6):1446-1448.
ma: a randomized PETHEMA/GEMstudy. 2012;120(8):1589-1596.
phase 3 Blood.
15. Usmani SZ, Rodriguez-Otero P, Bhutani M, Mateos MV, Miguel JS. Defining and treat- ing high-risk myeloma. Leukemia. 2015;29(11):2119-2125.
16. SonneveldP,Avet-LoiseauH,LonialS,etal. Treatment of multiple myeloma with high-
haematologica | 2018; 103(5)
Autologous SCT for extramedullary myeloma
897